Table 3 Study design and top three most commonly reported outcome categories
Type of study | First most commonly reported outcome category | Second most commonly reported outcome category(ies) | Third most commonly reported outcome category(ies) |
|---|---|---|---|
Retrospective cohort study (n = 21) | Duration of hospital stay (16%) | NAS symptoms (13%) | Duration of pharmacotherapy (12%) |
Randomized controlled trial (n = 10) | Duration of pharmacotherapy (22%) | Duration of hospital stay (12%) | Adjunctive therapy (10%) |
Adverse events (10%) | |||
Prospective cohort study (n = 5) | Dose of pharmacotherapy (22%) | Duration of pharmacotherapy (17%) | Duration of hospital stay (11%) |
NAS symptoms (11%) | |||
Initiation of pharmacotherapy (11%) | |||
Quality improvement (n = 4) | Duration of hospital stay (15%) | Adverse events (12%) | Initiation of pharmacotherapy (8%) |
Cost of treatment (12%) | Readmission to hospital (8%) | ||
Advancing level of care (NICU admission) (12%) | Feeding breast milk (8%) | ||
Custody at discharge (8%) | |||
Case series and case report (n = 4) | Miscellaneous single outcomes (25%) | Duration of pharmacotherapy (17%) | Duration of hospital stay (8%) |
NAS symptoms (17%) | Dose of pharmacotherapy (8%) | ||
Adverse events (17%) | Adjunctive therapy (8%) | ||
Qualitative study (n = 1) | NAS symptoms (100%) | ||
Mixed method (n = 1) | Feeding breast milk (100%) | NAS symptoms (25%) | |
Initiation of pharmacotherapy (25%) | |||
Prospective within-subject study(n = 1) | Miscellaneous single outcomes (100%) |